Given its importance in cancer/leukemia, a number of PLK1 inhibitors have been developed and clinically tested for their safety (Gjertsen and Schöffski, 2015; Gopalakrishnan et al., 2018; Kobayashi et al., 2015; Rudolph et al., 2009). This evidence concerns the gene PLK1 and cancer.